Clofazimine Effect on Cutaneous Leishmaniasis
Not Applicable
- Conditions
- Cutaneous Leishmaniasis.Cutaneous Leishmaniasis
- Registration Number
- IRCT138710251543N1
- Lead Sponsor
- Fars University of Medical Sciences and Health Services
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Age more than 12 y/o, duration of disease less than 2month, no anti-leishmania (Glucantim, Rifampin, Azithromycin) treatment since 1 month prior to study,
Exclusion criteria: Lesion on face and joint, pregnancy, lactation, severe diseases including hepatic, renal and cardiac diseases
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Complete healing with re-epithelialization of cutaneous lesion. Timepoint: 3 week. Method of measurement: Physical examination and change of score, including: erythema, induration, ulceration and size of lesions.
- Secondary Outcome Measures
Name Time Method Adverse effect. Timepoint: 3 weeks. Method of measurement: Physical examination and medical history.